Clinicians Involved in Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infection, and Sexually Transmitted Infections in Substance.

Slides:



Advertisements
Similar presentations
Enhanced Behavioral Surveillance Lessons Learned for Gonorrhea Control 2004 National STD Prevention Conference Philadelphia, PA March 2004.
Advertisements

Title: PEOPLE LIVING WITH HIV/AIDSIN EGYPT: ROLE OF COMMUNITY PHARMACIST Authors: Nahla Maher Hegab Pharmacy graduate. Institution: College of pharmacy,
The effect of gender specific HIV prevention interventions on heterosexual anal sex among men and women in substance abuse treatment Donald A. Calsyn,
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
NIDA Director’s Report to the National Advisory Council on Drug Abuse National Advisory Council on Drug Abuse February 14, 2001.
Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.
Predictors of HIV Transmission Risk among Patients in Care: Results from the SPNS Prevention with Positives Initiative Stephen F. Morin, PhD Principal.
What the Heck is the CTN Anyway? The NIDA National Drug Abuse Treatment Clinical Trials Network.
Motivational Interviewing to Improve Treatment Engagement and Outcome* The effect of one session on retention Research findings from the NIDA Clinical.
HIV/AIDS-Related Health Services in Substance Abuse Treatment Programs Authors & Affiliations Lawrence S. Brown, Jr, MD, MPH, Steven Kritz, MD, Edmund.
Illustrating HIV/AIDS in the United States African American University Treatment and Science College Training Alexandra Ricca, MPH Emory University Friday,
STD Testing Protocols, STD Testing, and Discussion of Sexual Behaviors in HIV Clinics in Los Angeles County Melanie M. Taylor MD, MPH Los Angeles County.
Hepatitis C Virus Services Offered by Substance Abuse Treatment Programs in the U.S. E. J. Bini, MD, MPH; S. Kritz MD; L.S. Brown, MD, MPH; J. Robinson,
Factors Associated with HIV Viral Load Suppression among HIV-positive Adults in Care in Washington State in 2009 Council of State and Territorial Epidemiologists.
STATE POLICIES & AVAILABILITY OF INFECTION- RELATED SERVICES IN SUSTANCE ABUSE TREATMENT PROGRAMS – CONNECTED AT THE HIP? The NIDA Clinical Trials Network.
HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse,
IRB and the Community Member How You Can Get Involved Mary Lou Smith Elda Railey Conference Call Series on IRBs and Ethical Issues in Research Co-sponsored.
States and Substance Abuse Treatment Programs: Priorities, Guidelines and Funding for Infection-related Services S. Kritz, MD; L.S. Brown, MD, MPH; R.
The National Child Traumatic Stress Network The National Child Traumatic Stress Network is supported through funding from the Donald J. Cohen National.
Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.
The National Program of Cancer Registries: Enhancing Cancer Incidence Data … Hannah K. Weir, PhD Division of Cancer Prevention and Control Centers for.
FUTURE HIV RESEARCH EFFORTS PLANNED FOR THE CLINICAL TRIALS NETWORK James L. Sorensen, Ph.D. Susan Tross, Ph.D. Raul Mandler, M.D. University of California,
Relationships between State Policies and the Availability of Services for HIV/AIDS, Hepatitis C Viral Infection, and Sexually Transmitted Infections in.
Poverty and HIV Infection: NHBS National* and San Diego Findings Vanessa Miguelino-Keasling, MPH National HIV Behavioral Surveillance System.
The NIDCR funded Collaborating Research Centers to Reduce Oral Health Disparities (CRCROHD) represent an innovative approach to understanding determinants.
The NIDA Clinical Trials is conducting the Prescription Opioid Addiction Treatment Study (POATS) – a multi- site trial examining different lengths and.
HIV Risk-Reduction: Counselor Training for a Randomized Clinical Trial Louise Haynes 1, Tim Matheson 2, Kathleen Brady 1, Lisa Metsch 3 1 Psychiatry and.
Sexually Transmitted Disease Surveillance 2011 Division of STD Prevention.
SSuN Cycle 2 Conference call #5 Population-based gonorrhea surveillance Lori Newman & Kristen Mahle November 13, 2008.
Provider knowledge of California confidentiality laws: Associations with self-confidence and training Kapphahn C, MD, MPH 1, Rao S, MS, MPH 2, Jesser C,
Relationships Between HIV Disease Knowledge, Opinions, Training, Experience, And Service Availability At Substance Abuse Treatment Programs Data Source.
HIV/AIDS-Related Services in Substance Abuse Treatment Settings: Preliminary Results The NIDA Clinical Trials Network Lawrence S. Brown, Jr., MD, MPH,
STD Surveillance Network (SSuN) Cycle 2 Objectives Lori Newman & Kristen Mahle SSuN Principal Collaborators Meeting Atlanta, GA December 2, 2008.
Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse.
Increased exposure to an HIV risk reduction protocol associated with a reduction in drug abuse severity Louise F. Haynes 1 ; Rickey E. Carter 1 ; Amy E.
Elizabeth WellsDennis Daley School of Social WorkWestern Psychiatric Institute University of WashingtonUniversity of Pittsbu rgh Supported by Grants #
UNITED STATES CONFERENCE ON AIDS MONDAY, SEPTEMBER 9, 2013 NEW ORLEANS, LA Will Community Involvement in Test Link to Care, Plus Treat Research (HPTN 065)
HIV TESTING IN DRUG ABUSE TREATMENT James L. Sorensen, Ph.D. University of California, San Francisco and San Francisco General Hospital Presentation at.
Epidemiologic Studies Consortium Research CTCA meeting October 22, 2010 Lisa Pascopella, PhD, MPH California Department of Health Services.
Participants were recruited from 6 drug free, psychosocial treatment (PT) and 5 methadone maintenance (MM) programs (N = 628) participating in a NIDA Clinical.
Adoption of HIV Counseling and Testing Following Completion of Randomized Clinical Trial Louise Haynes 1, Beverly Holmes 2 Camille Peay 2, Lisa Metsch.
Reducing Sex under the Influence for Substance Abuse Treatment Patients Symposium Presentation at the American Psychological Association Annual Convention,
The HMO Research Network (HMORN) is a well established alliance of 18 research departments in the United States and Israel. Since 1994, the HMORN has conducted.
Background  The CDC recommends universal and routine HIV screening in all healthcare settings, including hospitals [MMWR 52(15), ; 2003].  The.
Research Meets Practice and Beyond: Clinical Implementation of HIV Rapid Testing Dissemination Workshop October, 2009 Louise Haynes, MSW Beverly Holmes,
Adoption of HIV Counseling and Testing Following Completion of Randomized Clinical Trial Louise Haynes 1, Beverly Holmes 2, Anna Amberg 2, Kathleen Brady.
Barriers to Providing Health Services for HIV/AIDS, Hepatitis C Virus Infection, and Sexually Transmitted Infections in Substance Abuse Treatment Programs.
Clarity of State Guidance on Infection-Related Health Services in Substance Abuse Treatment Programs L.S. Brown, MD, MPH; S. Kritz, MD; J. Rotrosen, MD;
Finding a Predictive Model for Post-Hospitalization Adverse Events Henry Carretta 1, PhD, MPH; Katrina McAfee 1,2, MS; Dennis Tsilimingras 1,3, MD, MPH.
Hepatitis B Virus and Hepatitis C Virus Services Offered by Substance Abuse Treatment Programs in the United States E. J. Bini, MD, MPH; S. Kritz MD; L.S.
Sex under the Influence is Common for Substance Abuse Treatment Patients Donald Calsyn, Ph.D. 1,2, Mary Hatch-Maillette, Ph.D. 1, Suzanne Doyle, Ph.D.
Teaching Condom Use Skills: Practice is Superior to Observation Donald Calsyn, Ph.D. 1,2, Melinda Godinez, M.S.W. 3, Suzanne R. Doyle, Ph.D. 1, Mary Hatch-Maillette,
Implementation of an Electronic Information System to Enhance Practice at an Opioid Treatment Program L.S. Brown, S. Kritz, M. Chu, C. Madray, C. John-Hull.
STDs in Men Who Have Sex with Men Sexually Transmitted Disease Surveillance 2009 Division of STD Prevention.
Meg Brunner, MLIS; Nancy Sutherland, MLS Alcohol and Drug Abuse Institute, University of Washington (WA Node) The NATIONAL DRUG ABUSE TREATMENT CLINICAL.
Relationships Between the Availability of Infection-Related Services & Availability of Services Tailored for Subpopulations in Substance Abuse Treatment.
Disparities in Infection-Related Services in Substance Abuse Treatment Programs for Underserved Populations L.S. Brown, MD, MPH; S. Kritz, MD; E. Bini,
Harold I Perl, PhD Center for the Clinical Trials Network National Institute on Drug Abuse 8 th Conference of INEBRIA Boston, MA September 23, 2011.
Housing Status and HIV Risk Behaviors Among Homeless and Housed Persons with HIV in the United States The findings and conclusions in this presentation.
Background  Substance abusers are at risk for HIV and other STIs.  Anal intercourse (AI) is riskier than vaginal intercourse.  Studies of AI have focused.
NAAT identified chlamydial infections: Enhanced sensitivity, reduced transmissibility? Presenter: Maria Villarroel, MA Authors: Maria A. Villarroel, MA.
Implications and Limitations The Asthma H.E.L.P. program demonstrates that an asthma management program can be integrated into the casework process of.
Hepatitis B Virus and Hepatitis C Virus Services Offered by Substance Abuse Treatment Programs in the United States E. J. Bini, MD, MPH; S. Kritz MD; L.S.
Hepatitis C Consultation Services (844) | 9AM-5PM ET, M-F nccc.ucsf.edu The Clinician Consultation Center (CCC) provides up-to-date expert clinical.
Hatch-Maillette, M. 1, Calsyn, D. A1,2, Doyle, S. 1, Woods, A
Evaluation Report: April 1, 2015 – March 31, 2016
Evaluation Period: January 1, 2016 – December
C-SCOPE: Survey on the Management of HCV in addiction clinics treating Patients on Opiate Agonist Therapies: a global perspective July 2017.
Treatment for PTSD and SUD:
Presentation transcript:

Clinicians Involved in Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infection, and Sexually Transmitted Infections in Substance Abuse Treatment Programs: the National Drug Abuse Treatment Clinical Trials Network L.S. Brown, MD, MPH; S. Kritz, MD; J. Rotrosen, MD; R.J. Goldsmith, MD; E. Bini, MD, MPH; J. Robinson, MEd, and the NIDA Clinical Trials Network Infections Study (CTN-0012) Team Poster Presentation at the Annual Meeting of the American Society on Addiction Medicine, San Diego, CA – May 5, 2006

ABSTRACT ABSTRACT In the US, users of illicit drugs will largely sustain the epidemics of HIV/AIDS, hepatitis C (HCV), and sexually transmitted infections (STI). Substance abuse treatment programs can play a major role in stemming these epidemics. A nationwide study, sponsored by the National Drug Abuse Treatment Clinical Trials Network (NIDA CTN) examines these three infection groups from the perspective of administrators and clinicians working in substance abuse treatment programs, and the states within which they are located. The NIDA CTN has over 100 Community Treatment Programs (CTPs) with over 300 discreet substance abuse treatment sites in 17 nodes across the US. Three surveys were developed; one each for substance abuse treatment program administrators and clinicians, and one for state health and substance abuse department administrators. This report examines HIV/AIDS, HCV, and STI-related services provided by substance abuse treatment programs in the NIDA CTN from the perspective of the clinicians, medical and non-medical, expert and non-expert, working in these programs. The clinician survey looked at practices, program guidelines, knowledge, barriers, and opinions of clinicians caring for substance abusers within their program. Completed surveys were obtained from 1719 of 2207 targeted clinicians working at 265 substance abuse treatment sites. The breakdown of completed surveys was: (1) medical expert: 251; (2) medical non-expert: 115; (3) non-medical expert: 522; and (4) non- medical non-expert: 831. The extensive data obtained from this group of clinicians will be presented to inform public policy to encourage “best practices” in treating these epidemic infections.

ACKNOWLEDGEMENTS Research Supported by National Institute on Drug Abuse (NIDA) as part of a Cooperative Agreement (1U10DA013046) with the NIDA CTN and other Protocol Team members consisting of: Research Supported by National Institute on Drug Abuse (NIDA) as part of a Cooperative Agreement (1U10DA013046) with the NIDA CTN and other Protocol Team members consisting of: –Randy Seewald, MD; Cheryl Smith, MD; Frank McCorry, PhD; Dennis McCarty, PhD; Donald Calsyn, PhD; Leonard Handelsman, MD; Steve Kipnis, MD –Patrick McAuliffe, MBA, LADC; Al Hassen, MSW; Karen Reese, CAC-AD; Sherryl Baker, PhD –Shirley Irons; Kathlene Tracy, PhD

Drug Abuse Treatment Clinical Trials Network Philadelphia Portland Los Angeles Charleston Miami Cincinnati Denver CTN Sites Seattle Raleigh/ Durham Long Island Boston San Francisco (CA/AZ Node) New York City Detroit Albuquerque Baltimore/Richmond New Haven 17 Nodes with 116 Community Treatment Agencies Reaching into 26 States!

STUDY SITES STUDY SITES New York Node: New York University, New York, NY New York Node: New York University, New York, NY South Carolina Node: Medical University of South Carolina, Charleston, SC South Carolina Node: Medical University of South Carolina, Charleston, SC Florida Node: University of Miami, Coral Gables, FL Florida Node: University of Miami, Coral Gables, FL Great Lakes Node: Wayne State University, Detroit, MI Great Lakes Node: Wayne State University, Detroit, MI Ohio Valley Node: University of Cincinnati, Cincinnati, OH Ohio Valley Node: University of Cincinnati, Cincinnati, OH Rocky Mountain Node: University of CO Health Sciences Center, Denver, CO Rocky Mountain Node: University of CO Health Sciences Center, Denver, CO New England Node: Yale University, New Haven, CT New England Node: Yale University, New Haven, CT Delaware Valley Node: University of Pennsylvania, Philadelphia, PA Delaware Valley Node: University of Pennsylvania, Philadelphia, PA Mid-Atlantic Node: Johns Hopkins Univ., Baltimore, MD; Medical College Mid-Atlantic Node: Johns Hopkins Univ., Baltimore, MD; Medical College of Virginia, Richmond of Virginia, Richmond Pacific Region Node: University of California at Los Angeles, CA Pacific Region Node: University of California at Los Angeles, CA Oregon Node: Oregon Health Sciences University, Portland, OR Oregon Node: Oregon Health Sciences University, Portland, OR Washington Node: University of Washington, Seattle, WA Washington Node: University of Washington, Seattle, WA Long Island Node: NY State Psychiatric Institute, New York, NY Long Island Node: NY State Psychiatric Institute, New York, NY North Carolina Node: Duke University, Raleigh/Durham, NC North Carolina Node: Duke University, Raleigh/Durham, NC Southwest Node: University of New Mexico, Albuquerque, NM Southwest Node: University of New Mexico, Albuquerque, NM Northern New England Node: McLean Hospital, Belmont, MA Northern New England Node: McLean Hospital, Belmont, MA California-Arizona Node: University of California at San Francisco, CA California-Arizona Node: University of California at San Francisco, CA

STUDY RATIONALE STUDY RATIONALE HIV/HCV/STI: major causes of excess morbidity and mortality in the US HIV/HCV/STI: major causes of excess morbidity and mortality in the US Substance abuse: a major vehicle for the transmission of infection Substance abuse: a major vehicle for the transmission of infection Scope of, and challenges to identifying, counseling, and treating persons with these infections in substance abuse treatment will assist in developing effective interventions Scope of, and challenges to identifying, counseling, and treating persons with these infections in substance abuse treatment will assist in developing effective interventions

IMPORTANT ABREVIATIONS IMPORTANT ABREVIATIONS HIV = Human Immunodeficiency Virus HIV = Human Immunodeficiency Virus AIDS = Acquired Immunodeficiency Syndrome AIDS = Acquired Immunodeficiency Syndrome HCV = Hepatitis C Virus HCV = Hepatitis C Virus STI = Sexually Transmitted Infections STI = Sexually Transmitted Infections CTP = Community Treatment Program CTP = Community Treatment Program CTN = Clinical Trials Network CTN = Clinical Trials Network SOP = Standard Operating Procedures SOP = Standard Operating Procedures IRB = Institutional (Human Subject) Review Board IRB = Institutional (Human Subject) Review Board

IMPORTANT DEFINITIONS IMPORTANT DEFINITIONS Treatment Program vs. NIDA CTN CTP Treatment Program vs. NIDA CTN CTP Services Assessed Services Assessed –Provider Education –Patient Education –Patient Risk Assessment –Patient Counseling –Patient Medical History & Physical Exam –Patient Biological Testing –Patient Treatment –Patient Monitoring Medical vs. Non-Medical Clinical Staff Medical vs. Non-Medical Clinical Staff ‘Expert’ Clinical Staff ‘Expert’ Clinical Staff

PRIMARY OBJECTIVES TO DESCRIBE: TO DESCRIBE: –Range of Infection-Related Services Available –Clinician Characteristics (training, knowledge, behavior) –Opinions –Perceived Barriers to Providing Infection-Related Services TO EXAMINE ASSOCIATIONS BETWEEN: TO EXAMINE ASSOCIATIONS BETWEEN: –CTPs ’ Availability of Selected Infection Services –Other Constructs Listed Above

DESIGN AND POPULATION STUDY DESIGN STUDY DESIGN –Cross-sectional Survey –Descriptive & Exploratory STUDY POPULATION STUDY POPULATION –CTP Clinicians

ETHICAL, REGULATORY & ADMINISTRATIVE CONSIDERATIONS Expedited IRB Approval Expedited IRB Approval Waiver of Informed Consent Waiver of Informed Consent Training for Node Protocol Managers Training for Node Protocol Managers

STUDY PROCEDURES STUDY PROCEDURES Node Protocol Managers Node Protocol Managers Information Sheet In Lieu of Informed Consent Information Sheet In Lieu of Informed Consent Survey Administration Survey Administration – Paper or Electronic – Central data acquisition

Clinician Surveys Statistician selects Clinicians from Treatment Programs based on contact information provided by Administrators Clinician surveys mailed Gathering sessions held for Clinicians to complete surveys Clinician completes survey online or mails to Data Center Completed surveys mailed to Data Center Data Center contacts non- responders after 30 days; flagged as non-responders after four weekly failed attempts If non-responder is a randomly selected Clinician, the next eligible Clinician on the selection list is sent a survey Data Center monitors the data entry of Clinicians Data Center contacts Clinicians to resolve any data queries Randomization

MEASUREMENTS & ANALYTICAL METHODS SAMPLING METHODOLOGY: At Each CTP … SAMPLING METHODOLOGY: At Each CTP … – All ‘Expert’ Clinicians Designated by the CTP – 10 randomly sampled ‘Non-Expert’ Clinicians, in a ratio of Medical:Non-Medical reflecting that of in a ratio of Medical:Non-Medical reflecting that of the CTP’s clinical staff the CTP’s clinical staff ANALYTIC METHODOLOGIES ANALYTIC METHODOLOGIES – ‘Experts’ will be analyzed separately – Clinicians may decline; next randomly selected person will be asked to participate selected person will be asked to participate

STATISTICAL ELEMENTS Sample Size and Precision of the Estimated Mean Sample Size and Precision of the Estimated Mean Analytic Plan Analytic Plan –Descriptive stats for survey variables –Principal Component or Cluster or Factor Analysis to group and reduce the number of variables –Structural Equation Models to test for associations

RESULTS Surveys Obtained from 1719 Clinicians of 2207 Targeted (78%) Surveys Obtained from 1719 Clinicians of 2207 Targeted (78%) 831 Non-Medical Non-Experts (48%) 831 Non-Medical Non-Experts (48%) 115 Medical Non-Experts (7%) 115 Medical Non-Experts (7%) 522 Non-Medical Experts (30%) 522 Non-Medical Experts (30%) 251 Medical Experts (15%) 251 Medical Experts (15%)

HIV/AIDS, HCV & STI-RELATED SERVICES IN SUBSTANCE ABUSE TREATMENT PROGRAMS: NIDA CTN ADMINISTRATOR RESPONSES (N=269) HIV/AIDSHCVSTIs SERVICE n (%) Provider Education 186 (69) 171 (63) 155 (57) Patient Education 226 (84) 200 (74) 205 (76) Risk Assessment 224 (89) 194 (77) 195 (77) History & Physical Examination 150 (56) 135 (50) 133 (49) Testing 131 (49) 93 (34) 109 (40) Counseling 178 (66) 159 (59) 163 (60) Treatment 103 (38) 78 (29) 92 (34) Monitoring 117 (43) 95 (35) 105 (39)

CLARITY OF HIV GUIDELINES: % OF CLINICIANS SCORING GUIDELINES AS CLEAR NON - EXPERT EXP EXPERT SERVICENon-MedMedicalNon-MedMedicalOVERALL Provider Education 50%55%56%49%52% Patient Education 57%60%66%54%60% Risk Assessment 57%54%65%59%60% History & Physical Exam 56%66%53%76%58% Testing35%47%42%59%41% Counseling49%52%54%58%52% Treatment43%55%46%55%47% Monitoring39%42%38%51%41%

CLARITY OF HCV GUIDELINES: % OF CLINICIANS SCORING GUIDELINES AS CLEAR NON - EXPERT EXP EXPERT SERVICENon-MedMedicalNon-MedMedicalOVERALL Provider Education 42%53%43%45%43% Patient Education 48%54%51%48%49% Risk Assessment 48%50%54%54%51% History & Physical Exam 53%64%50%74%56% Testing32%44%37%54%37% Counseling41%47%45%51%44% Treatment39%52%40%48%41% Monitoring35%42%32%43%36%

CLARITY OF STI GUIDELINES: % OF CLINICIANS SCORING GUIDELINES AS CLEAR NON - EXPERT EXP EXPERT SERVICENon-MedMedicalNon-MedMedicalOVERALL Provider Education 40%50%41%40%41% Patient Education 47%51%50%41%47% Risk Assessment 46%48%51%46%48% History & Physical Exam 49%64%49%73%53% Testing28%42%35%50%35% Counseling39%45%44%44%41% Treatment37%53%40%51%41% Monitoring32%42%31%43%34%

SUMMARY There is… There is… –substantial variation in the % of programs offering the various services for a particular infection group –consistency in the % of programs offering a particular service for all three infection groups

SUMMARY Clarity of guidelines for the 8 targeted services is generally about 50% or less for all three infection groups, with the following exceptions: Clarity of guidelines for the 8 targeted services is generally about 50% or less for all three infection groups, with the following exceptions: –History & Physical Exam (medical experts and non-experts) for all three infection groups –Patient Education and Risk Assessment (non- medical experts) for HIV

SUMMARY Significant opportunities exist to explore other associations between the HIV/AIDS, HCV & STI-related services offered and… Significant opportunities exist to explore other associations between the HIV/AIDS, HCV & STI-related services offered and… –Clinician Characteristics (training, knowledge, behavior) –Opinions –Perceived Barriers to Providing Infection- Related Services